PHILADELPHIA, PA — January 5, 2026 — Leads & Copy —
Medicus Pharma Ltd. (NASDAQ: MDCX) will present at Biotech Showcase 2026, scheduled for January 12–14 in San Francisco, according to a press release issued Jan. 5.
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will deliver the company presentation. Medicus is entering 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion programs, according to the company.
The presentation is scheduled for Tuesday, January 13, 2026, at 10:00 a.m. Pacific time in Yosemite A (Ballroom Level), Hilton San Francisco – Union Square.
The presentation will be webcast live and can be accessed here or from the company’s website. The webcast will be archived and available for replay after the presentation.
Medicus executives will be available for one-on-one meetings with institutional investors and prospective partners registered for the conference through the partneringONE portal.
Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies. The company aims to assemble decision-grade clinical, regulatory, and operational data packages aligned with this out-licensing strategy as data matures across its programs.
Medicus continues to advance SkinJect™, its novel, proprietary doxorubicin containing dissolvable microneedle array (D-MNA) platform, designed to non-invasively treat basal cell carcinoma (BCC) of the skin. Medicus completed enrollment of 90 patients in its randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study (SKNJCT-003) across nine clinical sites in the United States in December 2025. The study is designed to evaluate the safety, tolerability, and clinical efficacy of SkinJect™.
The company expects to report topline decision grade Phase 2 results in the first quarter of 2026 and to pursue an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026.
Previously disclosed positively trending interim findings demonstrated greater than 60% clinical clearance in an exploratory analysis conducted after more than 50% of patients of the then-targeted 60 patients in the study had been randomized.
Medicus has expanded the clinical and regulatory footprint of SkinJect™ to support development and partnering readiness. Approvals have been granted in the United States and the United Kingdom, and the first patient has been dosed in the United Arab Emirates.
In September 2025, the FDA provided positive feedback following a Type C meeting, supporting the potential use of the 505(b)(2) regulatory pathway for SkinJect™.
In November 2025, Medicus applied to the U.S. Food and Drug Administration (FDA) seeking eligibility for the FDA Commissioner’s National Priority Voucher (CNPV) program for SkinJect™.
Medicus announced a non-binding letter of intent with Reliant AI Inc. in December 2025 to collaborate on the development of an AI-driven clinical data analytics platform.
The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano’s proprietary mRNA technology with Medicus microneedle array delivery platform.
With the acquisition of Antev Limited (“Antev”) in August 2025, Medicus added Teverelix, a next generation GnRH antagonist targeting advanced prostate cancer patients with elevated cardiovascular risk and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate.
In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA), under physician supervision.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer (610) 636-0184 cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162 adjokovic@medicuspharma.com
Medicus Pharma Ltd. (Nasdaq: MDCX) is focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.
SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells.
Source: Medicus Pharma Ltd.
